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Chemotherapy exerts a variable effect on nutritional status. It is not known whether loss of body fat or fat-free mass (FFM) during
chemotherapy relates to diminished dietary intake, failure to meet elevated energy requirements, or to the presence of an acute-
phase response. We sought to determine prospective measurements of body mass and composition, resting energy expenditure,
energy and protein intake, and C-reactive protein over a course of chemotherapy in 82 patients with advanced cancer. There was a
large dropout from the study. Prospective measurements were obtained in 19 patients with non-small-cell lung cancer (NSCLC), 12
with metastatic melanoma and 10 with metastatic breast cancer. There were significant increases in energy intake among patients
with metastatic breast cancer, 873 (266–1480)kJ (mean 95% CI; Po0.01), and metastatic melanoma, 2513 (523–4503)kJ
(Po0.01). Breast cancer patients gained percentage body fat over the course of treatment, 2.1 (0.8–3.5%). Gain or loss of body fat
correlated to mean energy intake throughout chemotherapy in patients with NSCLC (Rs¼0.751; Po0.01) and metastatic breast
cancer (Rs¼0.617; Po0.05). The ability to meet or exceed energy requirements led to gains in body fat among patients with
metastatic breast cancer and NSCLC, but did not prevent loss of FFM in these groups.
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Treatment with chemotherapy is linked to loss of weight (i.e. loss
of body fat and/or fat-free mass (FFM)) in some, but by no means
all, cancer patients (Jardine et al, 1984; Jebb et al, 1994; Sarna et al,
1994). Whether loss of body fat and FFM are related to diminished
dietary intake or a failure to meet the elevated energy requirements
due to increases in resting energy expenditure associated with
cancer and its treatment is not resolved, as there are few
prospective data of energy balance among patients receiving
chemotherapy. A further consideration is the role of the acute-
phase response. This has been linked to weight loss through the
associated elevations in REE (Staal-van den Brekel et al, 1995) and
declines in dietary intake (Wigmore et al, 1997), but may also
specifically lead to the depletion of FFM (Simons et al, 1999). The
aim of this study was to examine whether changes in dietary
intake, resting energy expenditure or the acute-phase response
could explain changes in weight and body composition over the
course of chemotherapy. We therefore measured body mass, body
composition, energy expenditure, energy intake and C-reactive
protein (CRP) over several cycles of chemotherapy among patients
considered to be at high (non-small-cell lung cancer (NSCLC))
(Buccheri and Ferrigno, 2001) and metastatic melanoma (Smit et al,
1983), and low (metastatic breast) risk of wasting (Jardine et al,
1984).
PATIENTS AND METHODS
Patients
A total of 105 patients with advanced NSCLC (stage 111 or IV), 40
with metastatic melanoma and 30 with metastatic breast cancer
and scheduled to have chemotherapy were invited to enter the
study. None of the patients had received any cancer therapy, that
is, surgery, chemotherapy, radiotherapy or endocrine therapy
within the previous 3 months. Patients with a prognosis of less
than 2 months or severe endocrine abnormalities (e.g. diabetes
mellitus, or hyper/hypothyroidism) were excluded. None of the
patients received active nutritional intervention. Tumour response
to chemotherapy was evaluated according to the standard criteria
for melanoma, NSCLC (World Health Organisation, 1979) and
breast cancer patients (UICC, 1987).
Measurements
Patients were seen before commencing chemotherapy, prior to the
second chemotherapy cycle, and 1-month post completion of
chemotherapy (4–6 cycles). On each occasion, the following
measurements were determined:
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(biceps, triceps subscapular, suprailiac sites) using the equations of
Durnin and Womersley (1974). Skinfolds were measured three
times by a trained individual and the mean values calculated. The
coefficients of variation (CVs) for the determination of fat and FFM
from skinfolds by MH on different occasions were 1.1 and 0.8%.
Mid-arm muscle circumference (MAMC): was calculated from
tricep skinfold (TSF) and mid-arm circumference using standard
equations (Gurney and Jelliffe, 1973). The CV for the determina-
tion of MAMC measured by MH on different occasions was 1.5%.
Total body potassium:T o t a lb o d y
40K (TBK), a measure of lean
body mass, was measured using a NE8108 shadow shield whole-
body monitor (Nuclear Enterprises Ltd, Edinburgh, UK) over
40min. Relative changes only in
40K were determined. No attempt
was made to perform absolute measurements, as this would have
involved administration of radioactive isotopes. Sensitivity of the
detectors and instrumental stability were determined after each
measurement by performing a static count of potassium standard.
The measured values were corrected for changes in sensitivity of the
scanner and any change in body size of the patient between
measurements using a correction factor previously described
(Boddy et al, 1971). Coefficient of variation of measurement was 2%.
Energy and protein intakes: were determined from four-day
weighed food diaries completed before each assessment in
the week prior to the next chemotherapy cycle to avoid the
acute effects of the treatment on dietary intake. Energy intake
was determined using the Compeat 4 Nutritional Analysis
System (Carlson Bengston Consultants, London) based on the
5th Edition of McCance and Widdowson The Composition of
Foods (Holland, 1991).
Resting energy expenditure: was determined by indirect
calorimetry (Deltatrac Metabolic Monitor MBM 100, Datex
Instrumentation Corporation, Helsinki, Finland) under standar-
dised conditions (Harvie et al, 2004). Oral temperature was
recorded using the 3M Tempa-DOT Thermometer (3M Health
Care, USA) calibrated against a National Physics Laboratory
thermometer to confirm that patients were apyrexial, and had no
overt signs of infection. Resting energy expenditure was also
determined in healthy men and women recruited from hospital
staff who were one-to-one sex and age matched to the three
different cancer subgroups to control for this measurement.
Serum CRP: concentration was measured using a turbidometric
method with specific antibodies (Dako Patts, Denmark), measur-
ing the change in absorbance at 340 in an automated analyser
(Cobas Mira, Roche). Concentrations were determined using a
multi-point calibration curve (Hellsing, 1973) at a CRP concentra-
tion of 35mgl
 1. Coefficient of variation was 8.6%.
Performance status: of each patient was evaluated prior to
chemotherapy by assigning a Karnofsky score based on the ability
to carry out normal activities (Karnofsky and Burchenel, 1949).
Health-related quality of life: was assessed over the week prior to
each visit using the self-report general Functional Assessment of
Cancer Therapy Scale (FACT-G) (Cella et al, 1993). This 28-item
questionnaire assessed physical, functional, emotional and social
well-being. Higher scores are associated with better function, with
a maximum total score of 116.
Ethics
The study was approved by the South Manchester University
Hospitals NHS Trust Ethics Committee. All participants provided
written informed consent.
Statistical analysis
These were performed using the Statistical Package for Social
Sciences (SPSS 2001 version 10.1.4). Significance was accepted
at 0.05 level of probability. Resting energy expenditure in patients
with advanced NSCLC, metastatic melanoma and metastatic
breast cancer were compared to healthy controls using the
independent t-test.
Changes in outcome variable between baseline and the end of
chemotherapy were determined in each of the groups from paired
t-test (weight, body fat, % fat MAMC TBK, FACT-G, energy intake,
REE) and Wilcoxon sum of ranks test (CRP). P-values reported
have been corrected for the Bonferroni adjustment to allow for the
multiple testing. Values for individual skinfold measurements are
presented for completeness, but no statistical analyses were
undertaken on these data.
In view of the range of weight changes within each of the three
groups, post hoc correlation analyses were undertaken to examine
the relationships between mean energy intake, mean REE and
mean CRP (average of value prior to starting chemotherapy, prior
to second chemotherapy and one month after the final chemother-
apy treatment) and changes in weight and body composition (body
fat, FFM and MAMC) within each of the three groups, using
Pearson (energy intake, REE) and Spearman (CRP) correlation
coefficients.
RESULTS
Patients
In all, 43 of the 105 patients with NSCLC, 20 of the 40 patients with
metastatic melanoma and 19 of the 30 patients with metastatic
breast cancer were recruited. There was a large dropout from the
study. The reasons for not wishing to enter and for dropout from
the study are shown in Figure 1. Results are presented for the 19
NSCLC, 12 melanoma and 10 breast cancer patients who were
reassessed at the end of chemotherapy. All of the patients with
NSCLC, four with breast cancer and 11 with melanoma were newly
diagnosed with advanced disease. The remaining patients had
metastatic disease, which had progressed after previous cancer
therapy for advanced disease.
Baseline characteristics of patients recruited to the study and
assessed throughout chemotherapy within the advanced NSCLC,
melanoma and breast cancer groups are reported in Table 1.
Within the NSCLC and melanoma groups, patients assessed
throughout chemotherapy were less likely to have an acute-phase
protein response (APPR) at recruitment and more likely to have a
favourable response to chemotherapy compared to the patients
recruited the study. Non-small-cell lung cancer patients assessed
throughout chemotherapy also had higher baseline performance
scores than the group recruited to the study. In contrast, breast
cancer patients assessed throughout chemotherapy were no more
likely to have an APPR than the breast cancer patients recruited to
the study, but if anything appeared less likely to have a favourable
response to chemotherapy.
Among patients assessed throughout chemotherapy, those with
NSCLC had experienced a significant weight loss in the 4 months
prior to commencing chemotherapy. Median (range) weight
change¼ 7( 18–7)%. Weight changes in the previous 4 months
among patients with melanoma and breast cancer patients were
not significantly different from zero; however, some of the patients
within each group had lost or gained weight (Table 1). Che-
motherapy cycles lasted for between 3 and 7 months: median
(range) length of chemotherapy for patients with NSCLC¼5( 3–7 )
months; metastatic melanoma¼3.8 (3–6) months and metastatic
breast¼4.25 (4–6) months. A proportion of patients in each
group responded to chemotherapy (objective response; seven
NSCLC, one breast cancer, two melanoma, stable disease; three
NSCLC, four breast cancer and four melanoma or progressive
disease; nine NSCLC, five breast cancer and six melanoma). At 1
year after recruitment into the study, 13 of the 19 patients with
NSCLC, eight of the 12 patients with melanoma and three of the 10
patients with breast cancer had died.
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sInvited to study
Recruited
Reassessed at end
of chemotherapy 
NSCLC
n=105
• Too ill n=33
• Not want
additional
visits n=29
n=43
n=19
Breast cancer
n=30
• Too ill n=2
•
n=19
n=12
• Too ill n=6
• No longer
wish to
attend n=3
Melanoma n=40
• Too ill n=6
• Not want
additional
visits n=14
Not want
additional
visits n=9
n=20
n=10
• Too ill n=5
• No longer
wish to
attend n=3
• Died n=4
• Too ill n=12
• No longer
wish to attend n=6
• Incomplete dietary
records n=2 
Figure 1 Recruitment and dropout of participants to study.
Table 1 Baseline characteristics of patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer recruited to study and assessed t
hroughout chemotherapy
Advanced NSCLC Metastatic melanoma Metastatic breast cancer
Recruited 28 men,
15 women
Assessed 15 men,
four women
Recruited 13 men,
seven women
Assessed nine men,
three women
Recruited 20
women
Assessed 10
women
Age (years) 59.5 (8.5)
a 59.0 (7.1) 55.9 (9.2) 54.4 (7.1) 52.4 (9.7) 55.9 (6.5)
a
Weight change over the
previous 4 months (%)
 7(  27–16)
b  7(  18–7)  2.9 ( 1–6.0)  2.5 ( 13–11) 8.5 ( 27–27) 3 ( 15–12)
BMI (kgm
 2) 24.1 (4.3) 24.7 (4.5) 25.6 (3.0) 26.5 (2.7) 28.4 (8.5) 29.1 (7.2)
Smoker 38% 36% 25% 50% 20% 0%
Presence of APPR (%)
c 82% 56% 37% 18% 44% 40%
Karnofsky score 78 (11) 84 (10) 86 (11) 88 (12) 87.3 (12.4) 88 (12.5)
Medications (n)
Ibuprofen 5 2 2 2 2 0
Megace 3 2 0 0 0 2
Steroids
Predose with
chemotherapy
d
36 17 0 0 19 10
Daily prednisolone 15 4 2 0 1 0
Response to chemotherapy
Objective response 22% 37% 20% 17% 38% 10%
Stable disease 13% 16% 20% 33% 31% 40%
Progressive disease 65% 47% 60% 50% 31% 50%
aMean (s.d.).
bMedian (range).
cThe presence of an acute-phase protein response defined as CRP410mgl
 1 (Mahmoud et al, 2002).
dPredose of dexamethasone 8–40mg for
3–5 days with chemotherapy.
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Body mass and composition over the course of chemotherapy are
reported in Table 2a. Mean weight did not change over the course
of chemotherapy; however, some of the patients within each group
had appreciable gains or losses of weight. Patients with metastatic
breast cancer had a significant increase in % body fat mean change
(95% CI)¼2.1(0.8–3.5)% (Po0.05) and tendency to lose FFM;
mean (95% CI change)¼ 1.9( 4.9–1.1)kg (P¼0.074). Mean %
body fat and FFM remained unchanged among patients with
NSCLC and melanoma; however, some patients within each group
had lost or gained body fat and FFM. Patients with metastatic
melanoma had a significant decrease in MAMC mean (95% CI
change)¼ 1( 2,  0.2)cm (Po0.05). Baseline and post che-
motherapy TBK were assessed in 14/19 patients with NSCLC, 10/12
patients with metastatic melanoma and 8/10 patients with
metastatic breast cancer. Mean TBK remained unchanged in each
of the groups; however, patients within each of the groups had
experienced increases or decreases in TBK.
Energy intake and energy expenditure
Resting energy expenditure is expressed as absolute REE in
terms of kJ/24h, per kg, per kg FFM, and in order to standardise
for weight, height and age as a % of the resting energy, expenditure
was predicted from the Harris Benedict equation (% HB)
(Harris and Benedict, 1919). Patients with NSCLC had a
significantly higher REE compared to age- and sex-matched
healthy subjects. REE for patients with NSCLC was 112 (17)%
HB compared to 97.5% HB (10.4) in the controls (Po0.001).
The REE in patients with metastatic melanoma was 104 (11)% HB,
which was comparable to controls 101.4 (9)% HB (P¼0.41).
REE in patients with metastatic breast cancer was 98.6 (9.6)% HB,
which was also comparable to controls 95.0(9.5)% HB
(P¼0.234).
Changes in REE and energy intake are reported in Table 2b.
There were no significant overall changes in REE over the course of
chemotherapy, but a variable response in REE within each of the
three groups. Mean REE throughout chemotherapy did not relate
to change in weight, FFM or body fat over the course of
chemotherapy (data not shown).
Energy intake is expressed as an absolute intake in mJ and mJ
per kg body weight. Patients with melanoma and breast cancer had
significant increases in intakes of both energy and protein over the
course of chemotherapy (Po0.05). Mean energy intake did not
change for patients with NSCLC, but some patients had appreci-
able increases or decreases in energy intake over the course of
chemotherapy. Correlations between mean energy intake through-
out chemotherapy with change in weight, body fat and FFM in the
three groups are shown in Table 3a. Mean energy intake
throughout chemotherapy was significantly related to change in
weight (R¼0.603; Po0.01) and body fat (R¼0.751; Po0.01)
among patients with NSCLC (Figure 2A), and to the change in
body fat among patients with breast cancer (R¼0.617; Po0.05;
Figure 2B). Gains in weight and body fat among patients with
NSCLC and metastatic breast cancer are therefore related to higher
energy intakes. Change in weight and body fat were not related to
energy intake among patients with metastatic melanoma. Change
in FFM and MAMC did not relate to energy intake in any of the
groups.
Table 2 (a) Change in body mass and composition and health-related quality of life and (b) resting energy expenditure dietary intake and C-reactive
protein over the course of chemotherapy in patients with advanced NSCLC, metastatic breast cancer and metastatic melanoma
Advanced NSCLC: 15 males, four
females
Metastatic melanoma: nine males, three
females Metastatic breast cancer: 10 females
Prechemotherapy
D from
Prechemotherapy Prechemotherapy
D from
Prechemotherapy Prechemotherapy
D from
Prechemotherapy
(a)
Weight (kg) 72.8 (17.9)
a 0.94 ( 3,4.9)
b 81.0 (13.7) 0.24 ( 2.4, 2.9) 73.6 (18.9)  0.3 ( 5.7,5.1)
FFM (kg) 52.6 (11.6)  1.1 ( 3.1,0.9) 56.2 (9.8) 0.6 ( 1.6, 2.9) 45.7 (8.9)  1.9 ( 4.9,1.1)
Total fat (kg) 20.1 (8.5) 2.1 ( 1.2,5.3) 24.7 (6.6)  0.6 ( 3.4, 2.2) 27.9 (10.7) 1.5 ( 1.2,4.4)
% Body fat 26.9 (6.8) 1.7 ( 0.9, 4.3) 30.4 (5.5) 0.36 ( 3.6, 2.9) 37.3 (5.0) 2.1 (0.8, 3.5)*
Mid arm muscle
circumference (cm )
25 (3.2) 0.0 ( 0.9,0.9) 28.5 (2.4)  1(  2, 0.2)* 28 (2.0)  1(  2.3 0.4)
Total body potassium
(counts)
c
1115 (116) 8.0 ( 67–82) 1252 (210)  99 ( 235,35) 856 (189) 65 ( 54,186)
Tricep skin fold (mm) 11.1 (4.2) 1.0 ( 1.7, 3.6) 12.7 (4.6)  0.2 ( 3.4, 3) 16.0 (11.0) 1.8 ( 0.3 4.0)
Bicep skinfold (mm) 7.4 (3.5) 0.4 ( 2.5,3.3) 8.9 (3.4)  0.7 ( 3.5,2.1) 10.0 (7.0) 0.7 ( 3,5)
Subscapular skin fold
(mm)
18.0 (8.3) 3.3 ( 1.6–8.2) 21.6 (8.0) 1.4 ( 3.5,6.3) 29.0 (12.3) 3.3 ( 3.3,8.6)
Suprailiac skinfold (mm) 15 (10) 3.7 ( 0.5–8.0) 210.5 (9.0)  2(  9,5) 30.0 (16.1) 5.6 ( 0.7,12.0)
Fact-G score 86 (15)  3(  14,9) 89 (20) 0.8 ( 7, 8) 91 (14)  8(  3,12)*
(b)
REE (kJ) 7250 (1807)  334 ( 874, 205) 7217 (1380) 66 ( 418,548) 5887 (1334) 15 ( 297,170)
REE (kJkg
 1) 100 (19)  5.9 ( 8.8.34) 89 (4.6) 0 ( 7,8) 78 (6.7) 0.4 ( 10.5,10.5)
REE (kJkg
 1 FFM) 138 (21)  3(  11,5.5) 129 (11)  0.8 ( 12,10) 129 (12) 5 ( 0.1,11)
Energy intake (kJ) 10439 (3565) 381 ( 1209,1970) 7246 (2004) 600 (125,1076) 7552 (1840) 974(326,1230)**
Energy intake (kJkg
 1) 154 (66) 1.3 ( 23,26) 96 (25) 30 (8,50) 100 (3.1) 10 (4,17)**
Protein intake (g) 98.4 (33)  3.5 ( 17, 10) 72.3 (15) 22.5 (5.0,40.5) 71.3 (23.4) 7.3 (1.3,13)**
C-reactive protein
(mgl
 1)
17.5 (5–182)
d  0.3 ( 31,31) 5 (5, 24) 13.6 ( 4.3, 31.6) 6.5 (5,165) 2.4 ( 20, 25)
aMean (s.d.)
bMean (95% confidence intervals).
cNSCLC n¼14; metastatic melanoma n¼10; metastatic breast cancer n¼8.
dMedian (range). FFM¼fat-free mass; REE¼resting
energy expenditure. *Significant difference between prechemotherapy and post chemotherapy (Po0.05). **Significant difference between prechemotherapy and post
chemotherapy (Po0.01).
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Changes in FACT-G score are shown in Table 2a. Patients with
metastatic breast cancer had a significant decrease in FACT-G
score over the course of chemotherapy mean change (95% CI)¼8
( 3, 12) (Po0.05). Mean FACT-G score remained unchanged
among patients with NSCLC and metastatic melanoma.
Inflammatory response
In all, 35 of the 43 patients recruited with NSCLC (82%), 15 of the
40 patients with melanoma (37%) and 13 of the 30 (44%) with
breast cancer had an APPR defined as a CRP X10mgl
 1
(Mahmoud and Rivera, 2002). Among patients assessed through-
out chemotherapy, 11 of the 19 (56%) patients with NSCLC, two of
the 12 with melanoma (18%) and four of the 10 (40%) with breast
cancer had an APPR. There was no overall change in CRP over the
course of chemotherapy in any of the groups. A higher proportion
of the patients with melanoma had an APPR at the end of
chemotherapy compared to baseline (4/12 compared to 2/12),
while less metastatic breast cancer had an APPR at the end of
chemotherapy compared to baseline (2/10 compared to 4/10). The
proportion of patients with NSCLC with an APPR did not change
between baseline and the end of chemotherapy (7/19 compared to
8/19).
Correlations between mean CRP over the course of chemother-
apy and change in weight, body fat and FFM and MAMC are shown
in Table 3b. Among patients with NSCLC, there were negative
correlations between mean CRP and change in weight (Rs  0.549;
Po0.05), body fat (Rs  0.543; Po0.05) and MAMC (Rs  0.577;
Po0.05), but no relationship with change in FFM (P¼0.799).
Mean CRP level did not relate to changes in weight or body fat or
FFM in patients with breast cancer or melanoma. Among patients
with metastatic melanoma, there was a negative correlation
between mean CRP and change in MAMC (Rs  0.617; Po0.05).
The inflammatory response was therefore linked to loss of weight
body fat and MAMC among patients with NSCLC and loss of
MAMC among patients with melanoma.
DISCUSSION
This study provides one of the few longitudinal assessments of
energy balance (body composition, REE, dietary intake) and the
systemic inflammatory response (APPR) among advanced cancer
patients receiving chemotherapy. However, the high dropout rate
from the study illustrates the problem of making serial measure-
ments in such seriously ill populations. Selection bias is introduced
among the patients with NSCLC and melanoma because patients in
whom a second measurement could be made were probably among
the less seriously ill, but not apparently among those with
metastatic breast cancer.
We did not show the anticipated fall in body weight over the
course of chemotherapy among patients with NSCLC or melano-
ma, but there was a range of nutritional responses to chemother-
apy within these groups. Patients with breast cancer did not
change the overall weight, but had a propensity to gain fat and to
lose FFM. The ability to meet or exceed energy requirements led to
gains in weight and body fat among patients with NSCLC and
metastatic breast cancer, but did not prevent loss of FFM in either
group. The acute-phase response was linked to loss of weight and
body fat among patients with NSCLC and loss of MAMC among
patients with NSCLC and metastatic melanoma.
Table 3 (a) Pearson correlations between mean energy intake and (b)
Spearman correlation between mean level of C-reactive protein over the
course of chemotherapy and change in weight, fat, fat-free mass and mid-
arm muscle circumference over the course of chemotherapy in advanced
cancer patients
Change
in weight
Change
in
total
body
fat
Change
in
fat-free
mass
Change
in
mid-arm
muscle
circumference
(a)
NSCLC n¼19 0.603* 0.751**  0.213  0.196
Metastatic melanoma n¼12 0.427  0.112 0.329 0.259
Metastatic breast cancer n¼10 0.533 0.617* 0.383  0.050
(b)
NSCLC n¼19  0.549*  0.543*  0.069  0.577*
Metastatic melanoma n¼12 0.098  0.328  0.160  0.617*
Metastatic breast cancer n¼10  0.018 0.162 0.108 0.117
*Correlation is significant at the 0.05 level (two-tailed). **Correlation is significant at
the 0.01 level (two-tailed).
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Figure 2 (A) Correlation between mean energy intake and change in
body fat throughout chemotherapy among patients with NSCLC.
(B) Correlation between mean energy intake and change in body
fat throughout chemotherapy among patients with metastatic breast
cancer.
Energy balance in cancer patients receiving chemotherapy
MN Harvie et al
677
British Journal of Cancer (2005) 92(4), 673–680 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStudies of wasting and cancer have mainly been conducted
among patients with gastrointestinal (GI) malignancies (Bosaeus
et al, 2001). We deliberately studied cancers that do not directly
involve the GI tract to allow the effects of chemotherapy and the
metabolic effect of the cancer being treated to be assessed. We have
reconfirmed the variable change in weight among patients with
NSCLC (Sarna et al, 1994). Weight loss has previously been
reported among patients with metastatic melanoma (Smit et al,
1983). Weight maintenance in our patients may reflect less toxic
chemotherapy regimens, and control of emesis. Loss of mid arm
muscle alongside maintenance of FFM is these patients is
consistent with previous reports of disproportionate loss of mid-
arm muscle among cancer patients (Garrow, 1974). Advanced
breast cancer patients are considered to maintain good nutritional
status despite the presence of widespread metastatic disease
(Bozzetti et al, 1981; Jardine et al, 1984), although not all studies
concur (DeWys et al, 1981; Rowland-Payne et al, 1982). Gains in
fat and loss of FFM among patients with breast cancer in this study
represent a deterioration of nutritional status during chemother-
apy.
We have confirmed the presence of an elevated REE among
patients with NSCLC (Staal-van den Brekel et al, 1997a). Patients
with both metastatic melanoma and metastatic breast cancer
patients appeared to have a normal metabolic rate. There was a
variable response in REE over the course of chemotherapy within
each of the three groups. Previous reports have linked declines in
REE with a response to chemotherapy (Jebb et al, 1994), the
reasons for the varied response among patients in the current
study are unclear.
Contrary to expectations, energy intake increased over the
course of chemotherapy in patients with melanoma and breast
cancer. This may in part reflect an effect of the pre-dose
chemotherapy steroids among the breast cancer patients. Whether
steroids would continue to influence dietary intake 3 weeks post
treatment is not known. Increases in dietary intake were
particularly surprising in the patients with metastatic melanoma
since the majority of this population received highly emetogenic
decarbazine chemotherapy and did not receive steroids. Che-
motherapy-associated increases in dietary intake have previously
been reported in patients with early but not metastatic breast
cancer (Heasman et al, 1985). These increases are thought to be
mediated by chemotherapy-associated hunger, an increased sense
of well-being, or increased snacking to offset nausea (Grindel et al,
1989).
We have confirmed the prevalence of an APPR among patients
with NSCLC at 82% (Scott et al, 2003). The APPR also occurred,
but to a lesser extent, among patients with metastatic melanoma
(37%) and metastatic breast cancer (44%). Patients taking anti-
inflammatory medications, that is, steroids or ibuprofen, were
included from the analysis as they still had an APPR. C-reactive
protein would, if anything, be expected to be higher in these
patients if they had not taken anti-inflammatory medications. Loss
of weight and body fat was related to the level of CRP among
patients with NSCLC, which confirms the findings from an earlier
cross-sectional study (Scott et al, 1996).
The ability to meet or exceed energy requirements led to gains in
body fat but not FFM in patients with breast cancer and NSCLC.
This is consistent with findings from earlier nutritional interven-
tion studies (Evans et al, 1987; Ovesen et al, 1993). Gains in fat
have not been shown to confer advantages in terms of survival,
chemotherapy-associated toxicity or quality of life among patients
with NSCLC (Evans et al, 1987). The declines in health-related
quality of life alongside gains in body fat among patients with
metastatic breast cancer in the present study suggest that gains in
fat were not beneficial in this group. Gains in body fat may be
particularly deleterious for women with breast cancer. Higher
weight and stores of body fat are linked to poorer survival and
prognosis among patients with breast cancer (Petrelli et al, 2002;
Borugian et al, 2003), most likely mediated by the associated
higher levels of oestrogen (Leenen et al, 1994), insulin (Weinstock
et al, 1998) and bioavailable insulin-like growth factor-1 (IGF-1)
(Nam et al, 1997). Energy intake did not relate to changes in body
fat among patients with metastatic melanoma in the present study.
It is possible that the energy intake assessed 3 weeks after
chemotherapy may not have reflected any acute decrease in energy
intake in the immediate post-chemotherapy period. It also raises
the possibility that changes in fat mass among patients with
metastatic melanoma may be independent of energy balance and
instead influenced by the presence of lipid-mobilising factors such
as zinc-a 2 glycoprotein (Russell and Tisdale, 2002; Bing et al,
2004).
Preservation of FFM remains a major therapeutic challenge in
the management of the cancer patients linked to improvements in
functional capacity, prognosis (Tisdale, 2001), and quality of life
(Fearon et al, 2003). Our study highlights that adequate dietary
intake will not lead to gains in FFM during chemotherapy.
Previous studies have linked loss of FFM (Simons et al, 1999;
Fearon et al, 2003) to the presence of an inflammatory response in
advanced cancer patients not receiving active treatment. We were
unable to establish any links between CRP level and change in FFM
in any of our advanced cancer groups over the course of
chemotherapy. Loss of mid-arm muscle was linked to CRP among
patients with NSCLC and metastatic melanoma, suggesting that
loss of peripheral muscle mass at this site was linked to the
inflammatory response. Total body potassium is considered by
some to be a robust method of assessing lean body mass among
cancer patients (Mcmillan et al, 2000). We, however, failed to
replicate a previous report that declines in TBK in cancer patients
are linked to the APPR (Mcmillan et al, 1998) (data not shown). A
major distinction between the present and earlier reports that
linked loss of FFM and TBK to the APPR is that our cancer patients
were assessed throughout chemotherapy. Loss of FFM and TBK in
patients receiving chemotherapy may be a function of the
chemotherapy itself, which may limit protein synthesis (Herrmann
et al, 1981; Tayek and Chlebowski, 1992), or may relate to the
associated lower levels of hormones such as testosterone (Aaesebo
et al, 1991) and IGF-1 (Kajdaniuk and Marek, 2000). The use of
predose steroids among patients with NSCLC and breast cancer is
unlikely to have led to loss of FFM in the doses used (Picado et al,
1990). Declines in activity (secondary to chemotherapy associated
fatigue) may be a specifically linked to loss of FFM among
advanced cancer patients receiving chemotherapy. We did not
assess physical activity, but preliminary studies among advanced
cancer patients receiving chemotherapy have demonstrated home-
based resistance and moderate exercise programmes to be
efficacious in the preservation of FFM (Coleman et al, 2003).
The possible limitation of assessment of FFM from skinfolds
needs to be considered. No method of assessing lean (metabolically
active tissue) is entirely satisfactory, particularly among cancer
patients. All techniques (body potassium, dual emission X-ray
absorptiometry, body water, body density, body impedance, in
vitro neutron activation analysis (IVNAA)) make assumptions
about the relationship between the various body compartments
and what is being measured (Burkinshaw, 1990). FFM calculated
from skinfold relies on a relationship with body density (Durnin
and Womersley, 1974). It is, however, the most widely used and the
most robust of the techniques available. Hill et al (1978)
demonstrated a very close relationship between FFM and total
body nitrogen (protein) measured using IVNAA. Mid upper arm
muscle circumference is often used as an index of lean or fat-free
body mass, but in wasting conditions tends to diminish faster than
total body FFM (Garrow, 1974). Total body potassium is
considered to be an index of the functional body cell mass and
muscle mass (Moore, 1980). Previous studies have shown declines
of TBK in patients receiving chemotherapy with a variety of
tumours (Cohn et al, 1982) and testicular cancer (Hyltander et al,
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chemotherapy in patients in this study is unclear.
Small numbers of patients means that we were unable to assess
whether response to chemotherapy influenced food intake, REE,
body composition or APPR in each of the cancer groups. Response
to chemotherapy has been linked to declines in REE, and
preservation of FFM among patients with SCLC (Jebb et al,
1994) and declines in APPR (Staal-van den Brekel et al, 1997b).
Some of the differences in body composition between the cancer
groups may be in part due to gender effects (Harvie et al, 2003),
but we are unable to determine these gender effects from our
analysis.
This study adds to the body of data that shows the varied
nutritional response to chemotherapy even within individuals with
the same tumour stage. Higher energy intakes lead to gains in fat
among patients with advanced breast and lung cancer. Loss of FFM
throughout chemotherapy, however, does not appear to be linked
to inadequate intakes of energy or protein. Declines in MAMC
were linked to the presence of an APPR. Preservation of FFM
alongside chemotherapy treatments may not therefore be amen-
able to standard nutritional repletion. Further studies should
investigate the potential benefits of anti-inflammatory medications
(Fearon et al, 2003) and exercise (Coleman et al, 2003) on
preservation of FFM among advanced cancer patients receiving
chemotherapy.
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